SS Innovations International (NASDAQ: SSII) announced record second-quarter 2026 revenue of $13.9 million, a 39.4% increase from $10 million in the same period last year, driven by a 30.4% rise in installations of its SSi Mantra surgical robotic system to 30 units. The company's gross profit climbed 20% to $7.1 million, with a gross margin of 50.9%, reflecting improved operational efficiency despite a net loss of $2.7 million, or $0.01 per diluted share, compared to a net loss of $0.3 million a year earlier.
The robust performance underscores the growing adoption of SSi Mantra, which has now been installed in 224 systems across 12 countries. As of June 30, the company had completed 12,272 cumulative procedures using the system, including 175 telesurgeries. Notably, SS Innovations recently completed a robotic telesurgery spanning more than 13,600 miles between Colombia and India, demonstrating the system's capability to enable remote surgical procedures across vast distances. This achievement highlights the potential of telesurgery to expand access to specialized care in underserved regions.
Financially, the company reported $13.6 million in cash and cash equivalents with no long-term debt, positioning it to fund ongoing operations and regulatory efforts. SS Innovations anticipates that the U.S. Food and Drug Administration (FDA) will complete its review of the SSi Mantra's 510(k) premarket notification by the end of the first quarter of 2027. Additionally, the company believes it can secure European Union CE marking certification by the end of 2026. These milestones are critical for entering the U.S. and European markets, which represent significant growth opportunities.
The strong first-half performance, with revenue increasing 65.6% to $25 million and installations up 47.4% to 56, reflects the company's successful expansion strategy. SS Innovations aims to make robotic surgery affordable and accessible globally, a mission that resonates with healthcare providers seeking cost-effective solutions. The SSi Mantra's competitive pricing and user-friendly design position it as a viable alternative to more expensive robotic systems, potentially disrupting the market.
However, the increased net loss in Q2, from $0.3 million to $2.7 million, indicates higher operating expenses, likely due to investments in regulatory processes, research and development, and global expansion. Investors will be watching whether the company can achieve profitability as it scales. The successful telesurgery and growing procedure volume provide evidence of clinical acceptance, which is crucial for future revenue growth.
With regulatory approvals pending, SS Innovations is at a pivotal juncture. The company's ability to obtain FDA clearance and CE marking will determine its entry into two of the world's largest healthcare markets. The recent financial results and operational progress suggest that SS Innovations is well-positioned to capitalize on the increasing demand for minimally invasive surgical options. As the company continues to expand its installed base and procedure volume, its impact on global surgical care could be substantial.
For more information, the full press release is available at https://ibn.fm/nTMso.
